Ligand-induced internalization of the orexin OX 1 and cannabinoid CB 1 receptors assessed via N-terminal SNAP and CLIP-tagging

British Journal of Pharmacology

Volumn 162, Issue 6, 2011, Pages 1439-1452

  Ward, Richard J ^a   Pediani, John D ^a   Milligan, Graeme ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

cannabinoid; epitope tagging; G protein coupled receptor; insomnia; narcolepsy; orexin; receptor internalization; receptor trafficking

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; EPITOPE; LIGAND; OREXIN 1 RECEPTOR; OREXIN 1 RECEPTOR AGONIST; PROTEIN CLIP; RECEPTOR PROTEIN; SNARE PROTEIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CELL FUNCTION; CELL SURFACE; CONTROLLED STUDY; COVALENT BOND; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; INTERNALIZATION; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN VARIANT; QUANTITATIVE ANALYSIS; RECEPTOR BINDING; REGULATORY MECHANISM; SENSITIVITY ANALYSIS;

ALKYL AND ARYL TRANSFERASES; BENZOXAZOLES; CELL LINE; CELL MEMBRANE; CLONING, MOLECULAR; CYCLOHEXANOLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIGANDS; NEUROPEPTIDES; PHENYLUREA COMPOUNDS; PHOSPHORYLATION; PIPERIDINES; PLASMIDS; PYRAZOLES; PYRROLIDINES; RECEPTOR, CANNABINOID, CB1; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROPEPTIDE; THIAZOLES; UREA;

EID: 79951963422     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01156.x     Document Type: Article

References (48)

1. Adie EJ, Kalinka S, Smith L, Francis MJ, Marenghi A, Cooper ME, et al. (2002). A pH-sensitive fluor, CypHer 5, used to monitor agonist-induced G protein-coupled receptor internalization in live cells. Biotechniques 33: 1152-1154.
2. Adie EJ, Francis MJ, Davies J, Smith L, Marenghi A, Hather C, et al. (2003). CypHer 5: a generic approach for measuring the activation and trafficking of G protein-coupled receptors in live cells. Assay Drug Dev Technol 1: 251-259.
3. 3 muscarinic acetylcholine receptors analyzed by fluorescence resonance energy transfer (FRET) imaging and homogenous time-resolved FRET. J Biol Chem 285: 23318-23330.
4. 1 receptor signaling. Mol Endocrinol 20: 80-99. (Pubitemid 43011672)
5. Baccari MC, (2010). Orexins and gastrointestinal functions. Curr Protein Pept Sci [Epub ahead of print].
6. Bingham MJ, Cai J, Deehan MR, (2006). Eating, sleeping and rewarding: orexin receptors and their antagonists. Curr Opin Drug Discov Devel 9: 551-559. (Pubitemid 44378823)
7. Burch J, McKenna C, Palmer S, Norman G, Glanville J, Sculpher M, et al. (2009). Rimonabant for the treatment of overweight and obese people. Health Technol Assess 13: 13-22.
8. Canals M, Milligan G, (2008). Constitutive activity of the cannabinoid CB1 receptor regulates the function of co-expressed Mu opioid receptors. J Biol Chem 283: 11424-11434.
9. Coleman PJ, Renger JJ, (2010). Orexin receptor antagonists: a review of promising compounds patented since 2006. Expert Opin Ther Pat 20: 307-324.
10. Coman OA, Paunescu H, Coman L, Badarau A, Fulga I, (2008). Recent data on cannabinoids and their pharmacological implications in neuropathic pain. J Med Life 1: 365-375.
11. 1 receptors in hippocampal neurons. J Neurosci 21: 2425-2433. (Pubitemid 32240539)
12. Dalton GD, Bass CE, Van Horn CG, Howlett AC, (2009). Signal transduction via cannabinoid receptors. CNS Neurol Disord Drug Targets 6: 422-431.
13. 1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. J Biol Chem 281: 38812-38824. (Pubitemid 46042008)
14. Evans NA, Groarke DA, Warrack J, Greenwood CJ, Dodgson K, Milligan G, et al. (2005). Visualizing differences in ligand-induced beta-arrestin-GFP interactions and trafficking between three recently characterized G protein-coupled receptors. J Neurochem 77: 476-485. (Pubitemid 32298742)
15. Gautier A, Juillerat A, Heinis C, Corrêa IR Jr, Kindermann M, Beaufils F, et al. (2008). An engineered protein tag for multiprotein labeling in living cells. Chem Biol 15: 128-136. (Pubitemid 351253620)
16. Haasen D, Schnapp A, Valler MJ, Heilker R, (2006). G protein-coupled receptor internalization assays in the high-content screening format. Methods Enzymol 414: 121-139. (Pubitemid 44716220)
17. Heilker R, (2006). High content screening to monitor G protein-coupled receptor internalisation. Ernst Schering Found Symp Proc 2: 229-247.
18. 2+ influx. Br J Pharmacol 150: 97-104. (Pubitemid 46094674)
19. Kallal L, Benovic JL, (2002). Fluorescence microscopy techniques for the study of G protein-coupled receptor trafficking. Methods Enzymol 343: 492-506.
20. Kirkham TC, (2009). Cannabinoids and appetite: food craving and food pleasure. Int Rev Psychiatry 21: 163-171.
21. Kredel S, Wolff M, Wiedenmann J, Moepps B, Nienhaus GU, Gierschik P, et al. (2009). CXCR2 inverse agonism detected by arrestin redistribution. J Biomol Screen 14: 1076-1091.
22. Kroeger D, de Lecea L, (2009). The hypocretins and their role in narcolepsy. CNS Neurol Disord Drug Targets 8: 271-280.
23. Langmead CJ, Jerman JC, Brough SJ, Scott C, Porter RA, Herdon HJ, (2004). Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. Br J Pharmacol 141: 340-346. (Pubitemid 38250904)
24. Lee HK, Choi EB, Pak CS, (2009). The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents. Curr Top Med Chem 9: 482-503.
25. Lopez-Gimenez JF, Vilaró MT, Milligan G, (2008). Morphine desensitization, internalization, and down-regulation of the mu opioid receptor is facilitated by serotonin 5-hydroxytryptamine2A receptor co-activation. Mol Pharmacol 74: 1278-1291.
26. McLean AJ, Bevan N, Rees S, Milligan G, (1999). Visualizing differences in ligand regulation of wild-type and constitutively active mutant beta(2)-adrenoceptor-green fluorescent protein fusion proteins. Mol Pharmacol 56: 1182-1191.
27. Malherbe P, Borroni E, Gobbi L, Knust H, Nettekoven M, Pinard E, et al. (2009a). Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor. Br J Pharmacol 156: 1326-1341.
28. Malherbe P, Borroni E, Pinard E, Wettstein JG, Knoflach F, (2009b). Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists. Mol Pharmacol 76: 618-631.
29. Maurel D, Comps-Agrar L, Brock C, Rives ML, Bourrier E, Ayoub MA, et al. (2008). Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies: application to GPCR oligomerization. Nat Methods 5: 561-567. (Pubitemid 351761765)
30. Milasta S, Evans NA, Ormiston L, Wilson S, Lefkowitz RJ, Milligan G, (2005). The sustainability of interactions between the orexin-1 receptor and beta-arrestin-2 is defined by a single C-terminal cluster of hydroxy amino acids and modulates the kinetics of ERK MAPK regulation. Biochem J 387: 573-584. (Pubitemid 40685690)
31. Milligan G, (1999). Exploring the dynamics of regulation of G protein-coupled receptors using green fluorescent protein. Br J Pharmacol 128: 501-510. (Pubitemid 29504736)
32. Milligan G, (2004). G protein-coupled receptor dimerization: function and ligand pharmacology. Mol Pharmacol 66: 1-7. (Pubitemid 38822080)
33. Milligan G, (2007). G protein-coupled receptor dimerisation: molecular basis and relevance to function. Biochim Biophys Acta 1768: 825-835. (Pubitemid 46452542)
34. Milligan G, (2008). A day in the life of a G protein-coupled receptor: the contribution to function of G protein-coupled receptor dimerization. Br J Pharmacol 153 (Suppl. 1): S216-S229. (Pubitemid 351340980)
35. Neubauer DN, (2010). Almorexant, a dual orexin receptor antagonist for the treatment of insomnia. Curr Opin Investig Drugs 11: 101-110.
36. Pertwee RG, (2005). Pharmacological actions of cannabinoids. Handb Exp Pharmacol 168: 1-51.
37. Pertwee RG, Ross RA, (2002). Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 66: 101-121. (Pubitemid 34743589)
38. Sakurai T, (2005). Reverse pharmacology of orexin: from an orphan GPCR to integrative physiology. Regul Pept 126: 3-10. (Pubitemid 40037737)
39. Smart D, Jerman JC, Brough SJ, Rushton SL, Murdock PR, Jewitt F, et al. (1999). Characterization of recombinant human orexin receptor pharmacology in a Chinese hamster ovary cell-line using FLIPR. Br J Pharmacol 128: 1-3. (Pubitemid 29425260)
40. Smart D, Sabido-David C, Brough SJ, Jewitt F, Johns A, Porter RA, et al. (2001). SB-334867-A: the first selective orexin-1 receptor antagonist. Br J Pharmacol 132: 1179-1182. (Pubitemid 32234700)
41. Smith NJ, Stoddart LA, Devine NM, Jenkins L, Milligan G, (2009). The action and mode of binding of thiazolidinedione ligands at free fatty acid receptor 1. J Biol Chem 284: 17527-17539.
42. Sullivan SS, Guilleminault C, (2009). Emerging drugs for insomnia: new frontiers for old and novel targets. Expert Opin Emerg Drugs 14: 411-422.
43. Tirat A, Freuler F, Stettler T, Mayr LM, Leder L, (2006). Evaluation of two novel tag-based labelling technologies for site-specific modification of proteins. Int J Biol Macromol 39: 66-76. (Pubitemid 44066539)
44. Voisin T, Rouet-Benzineb P, Reuter N, Laburthe M, (2003). Orexins and their receptors: structural aspects and role in peripheral tissues. Cell Mol Life Sci 60: 72-87. (Pubitemid 36223118)
45. Walker JM, Hohmann AG, (2005). Cannabinoid mechanisms of pain suppression. Handb Exp Pharmacol 168: 509-554.
46. Ward RJ, Alvarez-Curto E, Milligan G, (2011). Using the Flp-Ina T-Rexa system to regulate GPCR expression. In, Willars G, Challiss JA, (eds.). Receptor Signal Transduction Protocols, 3rd Edition. Methods in Molecular Biology series. Humana Press: Totowa, NJ (in press).
47. Wu DF, Yang LQ, Goschke A, Stumm R, Brandenburg LO, Liang YJ, et al. (2008). Role of receptor internalization in the agonist-induced desensitization of cannabinoid type 1 receptors. J Neurochem 104: 1132-1143. (Pubitemid 351143650)
48. Zanella F, Lorens JB, Link W, (2010). High content screening: seeing is believing. Trends Biotechnol 5: 237-245.